QNRX vs. CLSE
QNRX (Quoin Pharmaceuticals Ltd DRC) is a stock, while CLSE (Convergence Long/Short Equity ETF) is Long-Short fund actively managed by Convergence Investment Partners. Over the past 3 years, QNRX returned -73.86%/yr vs 31.74%/yr for CLSE. At a 0.06 correlation, their price movements are largely independent.
Performance
QNRX vs. CLSE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, QNRX achieves a -69.44% return, which is significantly lower than CLSE's 26.05% return.
QNRX
- 1D
- -5.16%
- 1M
- -7.55%
- YTD
- -69.44%
- 6M
- -67.93%
- 1Y
- -49.31%
- 3Y*
- -73.86%
- 5Y*
- -85.89%
- 10Y*
- —
CLSE
- 1D
- 0.79%
- 1M
- 4.52%
- YTD
- 26.05%
- 6M
- 25.23%
- 1Y
- 51.69%
- 3Y*
- 31.74%
- 5Y*
- —
- 10Y*
- —
QNRX vs. CLSE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
QNRX Quoin Pharmaceuticals Ltd DRC | -69.44% | -36.64% | -86.73% | -71.21% | -91.59% |
CLSE Convergence Long/Short Equity ETF | 26.05% | 20.44% | 35.54% | 17.54% | -4.38% |
Correlation
The correlation between QNRX and CLSE is -0.11, meaning they tend to move in opposite directions. This is especially valuable for risk management - when one declines, the other has historically tended to hold steady or rise.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.11 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.00 |
Correlation (All Time) Calculated using the full available price history since Feb 22, 2022 | 0.06 |
The correlation between QNRX and CLSE shifts across timeframes, from -0.11 (1 year) to 0.06 (all time), reflecting how their relationship changes across market environments.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
QNRX vs. CLSE — Risk / Return Rank
QNRX
CLSE
QNRX vs. CLSE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Quoin Pharmaceuticals Ltd DRC (QNRX) and Convergence Long/Short Equity ETF (CLSE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| QNRX | CLSE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -4.08 | ||
| Sortino ratioReturn per unit of downside risk | -4.39 | ||
| Omega ratioGain probability vs. loss probability | 1.09 | 1.67 | -0.58 |
| Calmar ratioReturn relative to maximum drawdown | -0.61 | 10.71 | -11.32 |
| Martin ratioReturn relative to average drawdown | -0.98 | 38.98 | -39.96 |
Loading charts...
Drawdowns
QNRX vs. CLSE - Drawdown Comparison
The maximum QNRX drawdown since its inception was -100.00%, which is greater than CLSE's maximum drawdown of -16.45%. Use the drawdown chart below to compare losses from any high point for QNRX and CLSE.
Loading charts...
Drawdown Indicators
| QNRX | CLSE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -16.45% | -83.55% |
Max Drawdown (1Y)Largest decline over 1 year | -81.17% | -4.85% | -76.32% |
Max Drawdown (3Y)Largest decline over 3 years | -98.68% | -16.45% | -82.23% |
Max Drawdown (5Y)Largest decline over 5 years | -100.00% | — | — |
Current DrawdownCurrent decline from peak | -100.00% | -0.00% | -100.00% |
Average DrawdownAverage peak-to-trough decline | -81.53% | -3.57% | -77.96% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 50.56% | 1.33% | +49.23% |
Volatility
QNRX vs. CLSE - Volatility Comparison
Quoin Pharmaceuticals Ltd DRC (QNRX) has a higher volatility of 23.57% compared to Convergence Long/Short Equity ETF (CLSE) at 4.03%. This indicates that QNRX's price experiences larger fluctuations and is considered to be riskier than CLSE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| QNRX | CLSE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 23.57% | 4.03% | +19.54% |
Volatility (6M)Calculated over the trailing 6-month period | 60.92% | 10.52% | +50.40% |
Volatility (1Y)Calculated over the trailing 1-year period | 190.41% | 13.63% | +176.78% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 213.65% | 13.91% | +199.74% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 172.31% | 13.91% | +158.40% |
Dividends
QNRX vs. CLSE - Dividend Comparison
QNRX has not paid dividends to shareholders, while CLSE's dividend yield for the trailing twelve months is around 0.76%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
CLSE Convergence Long/Short Equity ETF | 0.76% | 0.95% | 0.93% | 1.21% | 0.85% |
QNRX Quoin Pharmaceuticals Ltd DRC | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
QNRX and CLSE have a correlation of -0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
QNRX has higher volatility (23.57%) compared to CLSE (4.03%). In terms of maximum drawdown, QNRX dropped -100.00% vs CLSE's -16.45%.
CLSE currently has the higher Sharpe Ratio (3.82 vs -0.26), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for QNRX and CLSE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer